-
1.发明公开SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH 有权替代品吡咯并嘧啶，ZUSAMMENSETZUNGEN DAVON UND BEHANDLUNGSVERFAHREN DAMIT
公开(公告)号：EP2945636A2
公开(公告)日：2015-11-25
申请号：EP14702393.1
申请日：2014-01-15
发明人： CALABRESE, Andrew Antony , JEFFY, Brandon David , ROBINSON, Dale , ZHU, Dan , HUANG, Dehua , ELSNER, Jan , BOYLAN, John Frederick , TEHRANI, Lida , NAGY, Mark, A. , RAHEJA, Raj, Kumar , ERDMAN, Paul , NARLA, Rama, K. , HARRIS, Roy, L. , TRAN, Tam, Minh , RIGGS, Jennifer R. , NING, Yuhong , XU, Shuichan
IPC分类号： A61K31/519 , C07D487/00 , A61P35/00
CPC分类号： A61K31/519 , A61K31/5377 , C07D471/04 , C07D487/04
摘要： The present invention relates to a compound of formula (I): and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof, wherein R 1 , R 2 , R 3 and L are as defined herein. Also provided is a compound or a pharmaceutical composition of the present invention for use in a method for treating or preventing breast cancer.
摘要翻译： 本文提供具有以下结构的吡咯并嘧啶化合物：其中R1，R2，R3和L如本文所定义，包含有效量的吡咯并嘧啶化合物的组合物，以及用于治疗或预防乳腺癌的方法，更特别是三阴性乳腺癌， 包括向有需要的受试者施用有效量的这种吡咯并嘧啶化合物。
-
公开(公告)号：EP2825169B1
公开(公告)日：2018-05-09
申请号：EP13713003.5
申请日：2013-03-14
IPC分类号： A61K31/4985 , A61P35/00
CPC分类号： A61K31/4985
摘要： Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer.
-
3.发明公开
公开(公告)号：EP2768500A2
公开(公告)日：2014-08-27
申请号：EP12780374.0
申请日：2012-10-18
发明人： XU, Shuichan , HEGE, Kristen, Mae , LOPEZ-GIRONA, Antonia , RAYMON, Heather , NARLA, Rama, K. , CHOPRA, Rajesh
IPC分类号： A61K31/4166 , A61K31/4188 , A61K31/4985 , C07D487/04
CPC分类号： A61K31/4985 , A61K31/4166 , A61K31/4188 , A61P35/00 , C07D471/04 , C07D473/00 , C07D487/04 , C07D498/04
摘要： Provided herein are methods for treating or preventing a solid tumor, non- Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
摘要翻译： 本文提供了用于治疗或预防患者中的实体瘤，非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向具有实体瘤，非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
-
公开(公告)号：EP2768500B1
公开(公告)日：2019-08-21
申请号：EP12780374.0
申请日：2012-10-18
发明人： XU, Shuichan , HEGE, Kristen, Mae , LOPEZ-GIRONA, Antonia , RAYMON, Heather , NARLA, Rama, K. , CHOPRA, Rajesh
IPC分类号： A61K31/4166 , A61K31/4188 , A61K31/4985 , C07D487/04 , A61P35/00 , C07D471/04 , C07D473/00 , C07D498/04
-
5.发明授权SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH 有权取代的吡咯并嘧啶化合物，其组合物及其治疗方法
公开(公告)号：EP2945636B1
公开(公告)日：2017-06-28
申请号：EP14702393.1
申请日：2014-01-15
发明人： CALABRESE, Andrew Antony , JEFFY, Brandon David , ROBINSON, Dale , ZHU, Dan , HUANG, Dehua , ELSNER, Jan , BOYLAN, John Frederick , TEHRANI, Lida , NAGY, Mark, A. , RAHEJA, Raj, Kumar , ERDMAN, Paul , NARLA, Rama, K. , HARRIS, Roy, L. , TRAN, Tam, Minh , RIGGS, Jennifer R. , NING, Yuhong , XU, Shuichan
IPC分类号： A61K31/519 , C07D487/00 , A61P35/00
CPC分类号： A61K31/519 , A61K31/5377 , C07D471/04 , C07D487/04
摘要： The present invention relates to a compound of formula (I): and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof, wherein R 1 , R 2 , R 3 and L are as defined herein. Also provided is a compound or a pharmaceutical composition of the present invention for use in a method for treating or preventing breast cancer.
摘要翻译： 本文提供具有以下结构的吡咯并嘧啶化合物：其中R 1，R 2，R 3和L如本文所定义，包含有效量的吡咯并嘧啶化合物的组合物，以及用于治疗或预防乳腺癌，更特别是三阴性乳腺癌的方法， 包括给有此需要的受试者施用有效量的这种吡咯并嘧啶化合物。
-
6.发明公开
公开(公告)号：EP1791831A2
公开(公告)日：2007-06-06
申请号：EP04811775.8
申请日：2004-11-19
IPC分类号： C07D403/04 , C07D401/14 , C07D403/12 , C07D403/14 , A61K31/4196 , A61K31/4709 , A61K45/06 , A61K31/53
CPC分类号： A61K31/4196 , A61K31/4709 , A61K31/519 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14
摘要： The present invention is directed to the use of single agents, which are compounds that target two or more kinases simultaneously, thus substantially avoiding resistance to therapy. The invention provides methods for the use for, administration to, and treatment of individuals having a variety of diseases or conditions associated with the activity of two or more kinases, comprising administration of one or more single agents, either alone or in combination with other therapies for the same disease or condition.
-
公开(公告)号：EP2908814B1
公开(公告)日：2019-12-25
申请号：EP13824539.4
申请日：2013-10-17
发明人： MORTENSEN, Deborah , RAYMON, Heather , NARLA, Rama, K. , HEGE, Kristen, Mae , FULTZ, Kimberly, Elizabeth , TSUJI, Toshiya
IPC分类号： A61K31/4985 , A61P35/00
-
公开(公告)号：EP2908814A2
公开(公告)日：2015-08-26
申请号：EP13824539.4
申请日：2013-10-17
发明人： MORTENSEN, Deborah , RAYMON, Heather , NARLA, Rama, K. , HEGE, Kristen, Mae , FULTZ, Kimberly, Elizabeth , TSUJI, Toshiya
IPC分类号： A61K31/4985 , A61P35/00
CPC分类号： A61K31/4985 , G01N33/5041
摘要： Provided herein are methods for treating or preventing prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having prostate cancer.
摘要翻译： 本文提供了用于治疗或预防前列腺癌的方法，其包括向患有前列腺癌的患者施用有效量的TOR激酶抑制剂。
-
9.发明公开
公开(公告)号：EP1692128A1
公开(公告)日：2006-08-23
申请号：EP04811774.1
申请日：2004-11-19
发明人： BHAGWAT, Shripad, S. , SATOH, Yoshitaka , SAKATA, Steven, T. , BUHR, Chris, A. , ALBERS, Ronald , SAPIENZA, John , PLANTEVIN, Veronique , CHAO, Qi , SAHASRABUDHE, Kiran , FERRY, Rachel , NARLA, Rama, K.
IPC分类号： C07D403/04 , C07D401/14 , C07D403/14 , C07D403/12 , A61K31/416 , A61K31/4196
CPC分类号： C07D403/12 , C07D401/14 , C07D403/04 , C07D403/14
摘要： This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.
-
10.发明公开COMBINATION THERAPY COMPRISING A DIHYDROPYRAZINO-PYRAZINE COMPOUND AND AN ANDROGEN RECEPTOR ANTAGONIST FOR TREATING PROSTATE CANCER 审中-公开与用于治疗前列腺癌的AND A DIHYDROPYRAZINOPYRAZINVERBINDUNG雄激素受体拮抗剂联合治疗
公开(公告)号：EP2986320A1
公开(公告)日：2016-02-24
申请号：EP14725326.4
申请日：2014-04-16
IPC分类号： A61K45/06 , A61K31/4985 , A61P35/00 , A61P35/04 , A61K31/4166
CPC分类号： A61K31/4985 , A61K31/4166 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)
